Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

VVT Med Announces Positive Clinical Data for ScleroSafe(R) Published in Peer-Reviewed Indian Journal of Vascular and Endovascular Surgery

Clinical Data Published in Peer-Reviewed Journal

By The Northwire Desk — AI Analysis Apr 30, 2026 · 08:30 VVTM · 0.2 VVT Med Inc.
Executive Summary
  • VVT Med Inc. announced the publication of a peer-reviewed clinical study in the Indian Journal of Vascular and Endovascular Surgery evaluating its ScleroSafe catheter-directed sclerotherapy system.
  • The prospective observational study demonstrated a 100% clinical success rate and high vein occlusion rates (95% at 30 days) in patients treated for symptomatic primary varicose veins.
  • The study reported no serious safety complications, such as deep vein thrombosis or skin necrosis, during the 90-day follow-up period.
  • The publication occurred on April 30, 2026, coinciding with the deadline for audited annual financial statements which were missed, triggering a Management Cease Trade Order (MCTO) application filed on April 17, 2026.
Material Impact
  • While the clinical data is positive and validates the efficacy of the ScleroSafe system, it does not resolve the critical regulatory compliance risk associated with the MCTO application.
  • The inability to file audited financial statements by the April 30 deadline due to "external disruptions" (Middle East conflict affecting Israel personnel) raises significant concerns regarding internal controls and transparency for investors.
  • The positive clinical news is incremental and expected following trial completion, rather than a transformative event that alters the fundamental risk profile of the company.
  • The MCTO restricts insiders from trading until filings are remedied by June 30, 2026, creating uncertainty around management liquidity and potential delisting if deadlines are missed again.
  • Consequently, the market impact is muted; the clinical success is overshadowed by the compliance failure, limiting upside potential despite the positive data.
VVTM · Price
Company Overview
  • VVT Med Inc. develops the ScleroSafe system, a non-thermal, non-tumescent (NT-NT) technology for treating venous disease via simultaneous sclerosant injection and blood aspiration.
  • The flagship product is FDA-cleared and CE-marked, targeting symptomatic primary varicose veins with claims of high efficacy and safety profiles.
  • Commercial traction has been demonstrated through distribution agreements in India ($3.7M commitment) and Europe (Italy/Vatican/San Marino), as well as an initial order from Northwell Health in the US.
  • The company is focused on expanding U.S. and global commercialization efforts alongside manufacturing capacity expansion.
Read the original news release →

More from VVT Med Inc.

Jun 26, 2026 · 06:45

VVT Med Expands European Commercial Footprint Through Exclusive Distribution Agreement in Greece

Other Jun 12, 2026 · 17:00

Bi-weekly regulatory update on delayed filings and ongoing MCTO restricts insider trading while commercial expansion continues.

Regulatory Jun 11, 2026 · 08:30

Early-stage venous disease device maker scales global distribution while navigating regulatory delays and dilutive capital raises.

Financings May 29, 2026 · 17:32

VVT Med’s Italian Breakthrough Overshadowed as Cease Trade Order Drags Shares to Multi‑Year Lows

Regulatory May 26, 2026 · 08:00

Operational Milestone Achieved Amidst Regulatory Overhang

Production / Operations May 15, 2026 · 17:31

Governance Risks Persist Despite Commercial Traction

Regulatory